Table 2 Summary of published case reports of generalized CSH treated in the era of novel agents
Reference | date of publication | Age | Sex | Underlying disease | Organ involvment | Evolution before diagnosis | Ig | Treatment | Haematological response | Organ response | Evolution |
|---|---|---|---|---|---|---|---|---|---|---|---|
Boudhabhay [7] | 2018 | 60 | M | multiple myeloma | cornea, kidney | 2 years | IgGkappa | bortezomib-lenalidomide-dexamethasone | PR | NO | End stage renal failure |
Wu [8] | 2017 | 48 | M | multiple myeloma | kidney | Unknown | IgGkappa | bortezomib-cyclophosphamide-dexamethasone | VGPR | NO | End stage renal failure |
Aline-Fardin[9] | 2015 | 69 | M | monoclonal gammopathy | mesenteric panniculitis, lympho node, kidney | 6 months | LC kappa | bortezomib-DXM | VGPR | YES | Persistent remission (12 months) |
Baird [10] | 2015 | 53 | F | lymphoplasmocytic lymphoma | lung, mediastinal lymph node, bone marrow | 18 months | IgM lambda | bortezomib-cyclophosphamide-dexamethasone-rituximab | VGPR | YES | Remission |
Hu [11] | 2012 | 48 | F | multiple myeloma | spleen, bone marrow | 2 years | IgGkappa | bortezomib-thalidomide-dexamethasone-rituximab | VGPR | YES | Remission |
Robak [12] | 2002 | 54 | M | lymphoplasmocytic lymphoma | spleen, bone marrow | 1 year | IgAkappa | ritixmab | PR | NO | Pancytopenia |